ARGENX SE Files 6-K for February 2024 Press Release
Ticker: ARGX · Form: 6-K · Filed: Feb 20, 2024 · CIK: 1697862
Sentiment: neutral
Topics: regulatory-filing, press-release, foreign-issuer
TL;DR
**ARGENX SE just dropped a 6-K, meaning new company news is out via a press release.**
AI Summary
ARGENX SE, a foreign private issuer, filed a Form 6-K on February 20, 2024, to report the issuance of a press release on the same date. The company, with Commission File Number 001-38097, is headquartered in Amsterdam, the Netherlands, and operates in the biological products industry. This filing indicates a routine disclosure of company news via a press release.
Why It Matters
This filing signals that ARGENX SE has released new information to the public, which could impact investor perception and stock performance.
Risk Assessment
Risk Level: low — This is a routine administrative filing indicating a press release, not a direct financial or operational risk.
Key Players & Entities
- ARGENX SE (company) — registrant
- February 20, 2024 (date) — date of filing and press release
- 001-38097 (other) — Commission File Number
- Amsterdam, the Netherlands (location) — principal executive offices
FAQ
What type of document did ARGENX SE file?
ARGENX SE filed a Form 6-K, which is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934'.
When was this 6-K filed and what event did it report?
The 6-K was filed on February 20, 2024, and it reported that ARGENX SE issued a press release on the same date.
What is ARGENX SE's Commission File Number?
ARGENX SE's Commission File Number is 001-38097.
Where are ARGENX SE's principal executive offices located?
ARGENX SE's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
Is ARGENX SE a domestic or foreign private issuer?
ARGENX SE is a foreign private issuer, as indicated by the form type 'Report of Foreign Private Issuer'.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-02-20 06:06:40
Filing Documents
- tm246370d1_6k.htm (6-K) — 12KB
- tm246370d1_ex99-1.htm (EX-99.1) — 27KB
- tm246370d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-24-025102.txt ( ) — 44KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: February 20, 2024 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel